Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

ProteinN (2)


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 1 - 10 records in total 13
    records per page




    A cannabinoid receptor agonist shows anti-inflammatory and survival properties in human SARS-CoV-2-infected iPSC-derived cardiomyocytes MESHD

    Authors: Luiz Guilherme H.S. Aragao; Julia T Oliveira; Jairo R Temerozo; Mayara A Mendes; Jose Alexandre Salerno; Carolina da S. G. Pedrosa; Teresa Puig-Pijuan; Carla Verissimo; Isis M Ornelas; Thayana Torquato; Gabriela Vitoria; Carolina Q. Sacramento; Natalia Fintelman-Rodrigues; Suelen da Silva Gomes Dias; Vinicius Cardoso Soares; Leticia R. Q. Souza; Karina Karmirian; Livia Goto-Silva; Diogo Biagi; Estela M. Cruvinel; Rafael Dariolli; Daniel R. Furtado; Patricia T. Bozza; Helena L. Borges; Thiago Moreno L. Souza; Marilia Zaluar P. Guimaraes; Stevens Rehen

    doi:10.1101/2021.02.20.431855 Date: 2021-02-21 Source: bioRxiv

    Coronavirus disease 2019 MESHD ( COVID-19 MESHD) is caused by acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), which can infect several organs and lead to loss of vital organ function, especially impacting respiratory capacity. Among the extrapulmonary manifestations of COVID-19 MESHD is myocardial injury MESHD, caused both directly and indirectly by SARS-CoV-2, and which is associated with a high risk of mortality. One of the hallmarks of severe COVID-19 MESHD is the "cytokine storm", at which point the immune system malfunctions, leading to possible organ failure MESHD and death MESHD. Cannabinoids are known to have anti-inflammatory properties by negatively modulating the release of pro-inflammatory cytokines. Herein, we investigated the effects of the cannabinoid agonist WIN 55,212-2 (WIN) on SARS-CoV-2-infected MESHD human iPSC-derived cardiomyocytes (hiPSC-CMs). Although WIN did not modulate angiotensin-converting enzyme II, nor reduced SARS-CoV-2 infection MESHD and replication in hiPSC-CMs at the conditions tested, it had anti-inflammatory and protective effects by reducing the levels of interleukins 6, 8,18 and tumor necrosis factor-alpha HGNC tumor necrosis factor-alpha MESHD ( TNF HGNC-) and lactate dehydrogenase (LDH) activity in these cells without causing hypertrophic cardiac damage MESHD. These findings suggest that cannabinoids should be further investigated as an alternative therapeutic tool for the treatment of COVID-19 MESHD. HighlightsO_LIHuman iPSC-derived cardiomyocytes (hiPSC-CMs) express CB1 HGNC receptor. C_LIO_LIThe cannabinoid receptor agonist, WIN 55,212-2 (WIN), does not influence SARS-CoV-2 infection MESHD in hiPSC-CMs. C_LIO_LIWIN reduces inflammation MESHD and death MESHD in SARS-CoV-2-infected hiPSC-CMs MESHD. C_LI

    The Prognostic Value of Myocardial Injury MESHD in COVID-19 MESHD Patients and Associated Characteristics

    Authors: jian he; Bicheng Zhang; Quan Zhou; Wenjing Yang; Jing Xu; Tingting Liu; Haijun Zhang; Zhiyong Wu; Dong Li; Qing Zhou; Jie Yan; Cuizhen Zhang; Robert G. Weiss; Guanshu Liu; Zhongzhao Teng; Arlene Sirajuddin; Haiyan Qian; Shihua Zhao; Andrew E. Arai; Minjie Lu; Xiaoyang Zhou

    doi:10.21203/rs.3.rs-251810/v1 Date: 2021-02-17 Source: ResearchSquare

    Background: Since December 2019, Coronavirus disease 2019 MESHD ( COVID-19 MESHD) has emerged as an international pandemic. COVID-19 MESHD patients with myocardial injury MESHD might need special attention. However, understanding on this aspect remains unclear. This study aimed to illustrate clinical characteristics and the prognostic value of myocardial injury MESHD to COVID-19 MESHD patients. Methods: This retrospective, single-center study finally included 304 hospitalized COVID-19 MESHD cases confirmed by real-time RT-PCR from January 11 to March 25, 2020. Myocardial injury MESHD was determined by serum high-sensitivity troponin I (Hs-TnI). The primary endpoint was COVID-19 MESHD associated mortality. Results: Of 304 COVID-19 MESHD patients (median age, 65 years; 52.6% males), 88 patients (27.3%) died (61 patients with myocardial injury MESHD, 27 patients without myocardial injury MESHD on admission). COVID-19 MESHD patients with myocardial injury MESHD had more comorbidities ( hypertension MESHD, chronic obstructive pulmonary disease MESHD, cardiovascular disease MESHD, and cerebrovascular disease MESHD); lower lymphocyte counts, higher C-reactive protein HGNC ( CRP HGNC, median, 84.9 vs 28.5 mg/L, p<0.001), procalcitonin levels (median, 0.29 vs 0.06 ng/ml, p<0.001), inflammatory and immune response markers; more frequent need for noninvasive ventilation, invasive mechanical ventilation; and was associated with higher mortality incidence (hazard ratio, HR=7.02, 95% confidence interval, CI, 4.45-11.08, p<0.001) than those without myocardial injury MESHD. Myocardial injury MESHD (HR=4.55, 95% CI, 2.49-8.31, p<0.001), senior age, CRP HGNC levels, and novel coronavirus pneumonia MESHD ( NCP PROTEIN) types on admission were independent predictors to mortality in COVID-19 MESHD patients. Conclusions: COVID patients with myocardial injury MESHD on admission is associated with more severe clinical presentation and biomarkers. Myocardial injury MESHD and higher HsTNI are both strongest independent predictors to COVID related mortality after adjusting confounding factors. In addition, senior age, CRP HGNC levels and NCP PROTEIN types are also associated with mortality. Trial registration: Not applicable.

    Evaluation the relationship of left ventricular global longitudinal strain and laboratory parameters in discharged patients with COVID-19 MESHD: A follow-up study

    Authors: Derya BAYKIZ; Elif AYDUK GOVDELI; Pelin KARACA OZER; Ekrem Bilal KARAAYVAZ; Yunus CATMA; Alpay MEDETALIBEYOGLU; Atahan CAGATAY; Berrin UMMAN; Tufan TUKEK; Zehra BUGRA

    doi:10.21203/rs.3.rs-233011/v1 Date: 2021-02-11 Source: ResearchSquare

    Background The novel coronavirus infection MESHD ( COVID-19 MESHD) disease has spread rapidly and posed a great threat to global public health. The laboratory parameters and clinical outcomes of the disease in discharged patients remain unknown. In this study, we aimed to investigate the laboratory and echocardiographic findings of patients with COVID-19 MESHD after discharge and the relation between left ventricular global longitudinal strain (LVGLS) and inflammatory parameters in discharged patients.Methods A total of 75 patients recovering from COVID-19 MESHD as the study group were prospectively recruited from the COVID-19 MESHD outpatient clinic for their follow-up visits at a median 6 months after discharge. Patients were classified into groups according to pneumonia MESHD severity and impairment in LVGLS. Laboratory findings of patients both at admission and after discharge were evaluated and the relation with pneumonia MESHD severity at admission and LVGLS after discharge were analyzed.Results Serum ferritin, lactate dehydrogenase (LDH) and prohormone B-type natriuretic peptide (pro-BNP) levels after discharge were significantly higher in the study group than the control group (n = 44). Ferritin was found to be related to pneumonia MESHD severity. Serum ferritin and LDH values after discharge were significantly higher in patients with impaired LVGLS than those with preserved. There was a significant correlation between LVGLS, serum ferritin and LDH values after discharge (r = -0.252, p = 0.012; r = -0.268, p = 0.005, respectively).Conclusions Clinicians should pay close attention to the serum ferritin and LDH levels in discharged patients for predicting the severity of COVID-19 MESHD disease and early identification of subclinical left ventricular myocardial dysfunction MESHD.

    Findings from Cardiovascular Evaluation of NCAA Division I Collegiate Student-Athletes after Asymptomatic or Mildly Symptomatic SARS-CoV-2 Infection MESHD

    Authors: Calvin E Hwang; Andrea Kussman; Jeffrey W Christle; Victor Froelicher; Matthew T Wheeler; Kegan J Moneghetti

    doi:10.1101/2021.01.07.21249407 Date: 2021-01-08 Source: medRxiv

    ObjectivesThe risk of myocardial damage MESHD after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection MESHD has been controversial. There is an urgent need for data to support the appropriate level of cardiovascular screening for safe return-to-play. The purpose of this study is to report the incidence of abnormal cardiovascular MESHD findings in National Collegiate Athletic Association (NCAA) Division I student-athletes with a history of SARS-CoV-2 infection MESHD. MethodsThis is a case series of student-athletes at a single NCAA Division I institution who tested positive for SARS-CoV-2 by polymerase chain reaction (PCR) or antibody testing (IgG) from 4/15/2020 to 10/31/2020. From 452 athletes who were screened, 5,124 PCR and 452 antibody tests were completed. Student-athletes were followed through 12/31/2020 (median 104 days, range 64-182 days). Cardiac work-up included clinical evaluation, troponin level, electrocardiogram (ECG), and echocardiogram. Additional work-up was ordered as clinically indicated. Results55 student-athletes tested positive for SARS-CoV-2. Of these, 38 (69%) had symptoms of Coronavirus Disease MESHD ( COVID-19 MESHD), 14 (26%) had a positive IgG test, and 41 (74%) had a positive PCR test. Eight abnormal cardiovascular screening evaluations necessitated further testing including cardiac magnetic resonance imaging (cMRI). Two athletes received new cardiac diagnoses, one probable early cardiomyopathy MESHD and one pericarditis MESHD, while the remaining six had normal cardiac MRIs. ConclusionThese data support recent publications which recommend the de-escalation of cardiovascular testing for athletes who have recovered from asymptomatic or mildly symptomatic SARS-CoV-2 infection MESHD. Continued follow-up of these athletes for sequelae of SARS-CoV-2 is critical.

    Evaluation of Myocardial Injury Patterns and ST Changes among Critical and Non-critical Patients with Coronavirus-19 Disease

    Authors: Anam Liaqat; Rao Saad Ali-Khan; Muhammad Asad; Zakia Rafique; Syed Shahzad Hasan; Amy T Page; Xiwen Simon Qin

    doi:10.21203/rs.3.rs-106298/v1 Date: 2020-11-11 Source: ResearchSquare

    Background: Novel coronavirus disease MESHD ( COVID-19 MESHD) has led to a major public health crisis globally. Currently, myocardial damage MESHD is speculated to be associated with COVID-19 MESHD, which can be seen as one of the main causes of death MESHD of patients with COVID-19 MESHD. Therefore, in this study, we aim to investigate the effects of COVID-19 MESHD diagnosed patients on myocardial injury MESHD. Methods: A prospective study was conducted among 201 patients with COVID-19 MESHD in the Pakistan Military Hospital from April 1 to August 31, 2020, including non-critical cases and critical cases. COVID-19 MESHD patients were stratified as critical and non-critical according to signs and symptoms with those requiring intensive care and ventilator support as critical and those don’t require ventilator support as non-critical Results: A total of 201 COVID-19 MESHD patients with critical and non-critical categories presented with myocardial injury MESHD. All patients with myocardial injury MESHD had an elevation in CKMB and Trop 1 HGNC levels. Of these patients, 43.7% presented with new electrocardiography (ECG) changes, ST depression MESHD is observed in 36.3% patients, and 16.9% presented with abnormal electrocardiogram findings, with right ventricular dilatation and dysfunction MESHD. Results analyzed by a logistic regression model showing COVID-19 MESHD direct contribution to myocardial injury MESHD in these patients. Conclusion:  COVID-19 MESHD disease directly leads to cardiovascular damage MESHD among critical and non-critical patients. Myocardial injury MESHD is associated not only with abnormal ECG changes but also with myocardial dysfunction MESHD on echocardiography and more commonly observed among critical patients. 

    A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease

    Authors: Samarthkumar Thakkar; Shilpkumar Arora; Ashish Kumar; Rahul Jaswaney; Mohammed Faisaluddin; Mohammad Ammad Ud Din; Mariam Shariff; Kirolos Barssoum; Harsh P. Patel; Nirav Arora; Chinmay Jani; Sejal Savani; Christopher DeSimone; Siva Mulpuru; Abhishek Deshmukh

    doi:10.1101/2020.08.09.20171330 Date: 2020-08-11 Source: medRxiv

    The impact of coronavirus disease MESHD, 2019 ( COVID-19 MESHD), has been profound. Though COVID-19 MESHD primarily affects the respiratory system, it has also been associated with a wide range of cardiovascular (CV) manifestations portending extremely poor prognosis. The principal hypothesis for CV involvement is through direct myocardial infection MESHD and systemic inflammation MESHD. We conducted a systematic review of the current literature to provide a foundation for understanding the CV manifestations and outcomes of COVID-19 MESHD. PubMed and EMBASE databases were electronically searched from the inception of the databases through April 27th, 2020. A second literature review was conducted to include major trials and guidelines that were published after the initial search but before submission. The inclusion criteria for studies to be eligible were case reports, case series, and observation studies reporting CV outcomes among patients with COVID-19 MESHD infection. This review of the current COVID-19 MESHD disease and CV outcomes literature revealed a myriad of CV manifestations with potential avenues for treatment and prevention. Future studies are required to understand on a more mechanistic level the effect of COVID-19 MESHD on the myocardium and thus provide avenues to improve mortality and morbidity.

    Life-threatening cardiogenic shock in a pediatric patient with SARS-CoV-2-associated myocarditis treated with remdesivir: a case description and report of similar cases from the Literature

    Authors: Silvia Molinari; Lucia M.D. Colasanto; Maria L. Melzi; Alessandro Cattoni; Roberto Panceri; Michela Bombino; Giuseppe Lapadula; Andrea Biondi

    doi:10.21203/rs.3.rs-34802/v1 Date: 2020-06-12 Source: ResearchSquare

    BackgroundChildren are relatively spared from Coronavirus disease 2019 MESHD ( COVID-19 MESHD), but some severe cases have been reported. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection MESHD in children may affect the cardiovascular system. We hereby report about a case of myocarditis MESHD evolving to cardiogenic shock MESHD in a SARS-CoV-2 positive child.Case presentationAn otherwise healthy 12-year-old patient was admitted with fever MESHD, vomiting MESHD, diarrhoea and drowsiness MESHD, without any respiratory symptoms. He was diagnosed with COVID-19 MESHD on nasopharyngeal swab. He developed hypotension MESHD and cardiogenic shock MESHD. Bedside echocardiography revealed left ventricular impairment MESHD with an ejection fraction (LVEF) below 25%. Plasmatic markers of myocardial injury MESHD were remarkably raised, as well as inflammatory biomarkers, including procalcitonin (highest recorded value: 66 ng/mL) and interleukin-6 HGNC (8209 pg/mL). The child was transferred to Intensive Care Unit and he was treated with catecholamine support, mechanical ventilation and empiric anti-infectious therapy, including broad spectrum antibiotics and the antiviral agent remdesivir. All additional microbiological investigations yielded negative results. We observed a gradual improvement of LVEF within 5 days. A cardiac magnetic resonance confirmed the suspicion of myocarditis MESHD. After 21 days of hospitalisation, the child was discharged without sequelae.ConclusionsOur hypothesis is that the child suffered from SARS-CoV-2-induced fulminant myocarditis MESHD, probably in the setting of cytokine release syndrome (CRS). The peculiarity of this SARS-CoV-2 infection MESHD is the presence of cardiac failure MESHD in a previously healthy child without a respiratory illness MESHD. The positive outcome is in line with published Literature about the overall better prognosis of COVID-19 MESHD children compared to adults. Remdesivir, an investigational antiviral therapy, may have played a role on the clinical improvement of the child.

    Prevalence and Impact of Myocardial Injury in Patients Hospitalized with COVID-19 MESHD Infection

    Authors: Anuradha Lala; Kipp W Johnson; Adam J Russak; Ishan Paranjpe; Shan Zhao; Sulaiman Solani; Akhil Vaid; Fayzan Chaudhry; Jessica K De Freitas; Zahi A Fayad; Sean P Pinney; Matthew Levin; Alexander Charney; Emilia Bagiella; Jagat Narula; Benjamin S Glicksberg; Girish Nadkarni; James Januzzi; Donna M Mancini; Valentin Fuster

    doi:10.1101/2020.04.20.20072702 Date: 2020-04-24 Source: medRxiv

    Background: The degree of myocardial injury MESHD, reflected by troponin elevation, and associated outcomes among hospitalized patients with Coronavirus Disease MESHD ( COVID-19 MESHD) in the US are unknown. Objectives: To describe the degree of myocardial injury MESHD and associated outcomes in a large hospitalized cohort with laboratory-confirmed COVID-19 MESHD. Methods: Patients with COVID-19 MESHD admitted to one of five Mount Sinai Health System hospitals in New York City between February 27th and April 12th, 2020 with troponin-I (normal value <0.03ng/mL) measured within 24 hours of admission were included (n=2,736). Demographics, medical history, admission labs, and outcomes were captured from the hospital EHR. Results: The median age was 66.4 years, with 59.6% men. Cardiovascular disease MESHD ( CVD MESHD) including coronary artery disease MESHD, atrial fibrillation MESHD, and heart failure MESHD, was more prevalent in patients with higher troponin concentrations, as were hypertension MESHD and diabetes MESHD. A total of 506 (18.5%) patients died during hospitalization. Even small amounts of myocardial injury MESHD (e.g. troponin I 0.03-0.09ng/mL, n=455, 16.6%) were associated with death MESHD (adjusted HR: 1.77, 95% CI 1.39-2.26; P<0.001) while greater amounts (e.g. troponin I>0.09 ng/dL, n=530, 19.4%) were associated with more pronounced risk (adjusted HR 3.23, 95% CI 2.59-4.02). Conclusions: Myocardial injury MESHD is prevalent among patients hospitalized with COVID-19 MESHD, and is associated with higher risk of mortality. Patients with CVD MESHD are more likely to have myocardial injury MESHD than patients without CVD MESHD. Troponin elevation likely reflects non- ischemic MESHD or secondary myocardial injury MESHD.

    Analysis of the Clinical Characteristics of 77 COVID-19 MESHD Deaths

    Authors: Kaige Wang; Zhixin Qiu; Dan Liu; Jianfei Luo; Jiasheng Liu; Tao Fan; Chunrong Liu; Panwen Tian; Ye Wang; Zhong Ni; Shumin Zhang; Weimin Li

    doi:10.21203/rs.3.rs-23960/v1 Date: 2020-04-20 Source: ResearchSquare

    Purpose: For the emerging pandemic Coronavirus Disease MESHD Coronavirus Disease 2019 MESHD ( COVID-19 MESHD), no clear description on its deaths’ clinical characteristics and causes of death MESHD is available. Hence, this study analyzed clinical characteristics of 77 COVID-19 MESHD deaths, providing data support to further understand this disease.Method: A retrospective analysis of 77 COVID-19 MESHD deaths in East Branch, Renmin Hospital of Wuhan University from February 1 to March 7, 2020 was performed in clinical characteristics, laboratory results, causes of death MESHD, and subgroup comparison. Results: Totally 72.7% of the deaths (male-female ratio: 51:26, average age at death: 71, mean survival time: 17.4 days) had hypertension MESHD, heart disease MESHD, diabetes MESHD, chronic lung disease MESHD, and other comorbidities. Acute respiratory distress syndrome MESHD ( ARDS MESHD) and sepsis MESHD were the main causes of death MESHD. Increases in C-reactive protein HGNC ( CRP HGNC), lactate dehydrogenase (LDH), D-dimer and lactic acid (LAC), and decreases in lymphocyte, cluster of differentiation (CD) 4+ and CD8+ cells were common in laboratory results. Subgroup analysis showed: 1) Most female deaths had cough MESHD and diabetes MESHD. 2) The male proportion in young and middle-aged deaths was higher; while elderly deaths were more prone to myocardial injury MESHD and elevated CRP. 3 HGNC) There was no statistical difference between short-term and non-short-term survival subgroups. 4) CRP HGNC and LDH increased and CD4+ and CD8+ cells decreased significantly in patients with hypertension MESHD.Conclusions: The majority of COVID-19 MESHD deaths are males, especially the elderly with underlying diseases. The main causes of death include ARDS MESHD and sepsis MESHD. Most female deaths have cough MESHD and diabetes MESHD. Myocardial injury MESHD is common in elderly deaths. Patients with hypertension MESHD are prone to increased inflammatory index, tissue hypoxia MESHD and cellular immune injury.Authors Kaige Wang and Zhixin Qiu contributed equally to this work.

    Cardiovascular Vulnerability to COVID-19 MESHD in Cancer Survivors

    Authors: Beshay Zordoky

    id:10.20944/preprints202004.0128.v1 Date: 2020-04-08 Source: Preprints.org

    Coronavirus disease 2019 MESHD ( COVID-19 MESHD) has been declared a global pandemic by the World Health Organization on March 11, 2020. COVID-19 MESHD is caused by the Severe Acute Respiratory Syndrome Coronavirus-2 MESHD (SARS-Cov-2). Although primarily a respiratory disease MESHD, cardiovascular complications MESHD of COVID-19 MESHD have been increasingly recognized. In addition, higher fatality has been reported in COVID-19 MESHD patients with underlying cardiovascular diseases MESHD. Cancer MESHD survivors have a considerably increased risk for premature cardiovascular diseases MESHD, mainly due to cardiotoxic cancer MESHD treatments. Therefore, it is foreseeable that cancer MESHD survivors will be more vulnerable to cardiovascular complications MESHD caused by COVID-19 MESHD. In this review, three scenarios for increased cardiovascular complications of COVID-19 MESHD in cancer MESHD patients are proposed. In the first scenario, cardiotoxic cancer MESHD treatment and COVID-19 MESHD synergize to exacerbate direct myocardial damage MESHD. In the second scenario, cardiotoxic cancer MESHD treatment leads to a reduced cardiac reserve in cancer MESHD survivors, making them more vulnerable to COVID-19 MESHD in a “two-hit” model. The third scenario suggests that several shared risk factors may aggravate cardiovascular complications MESHD caused by both cancer MESHD treatment and COVID-19 MESHD. Taken together, cancer MESHD survivors may be more vulnerable to cardiovascular complications MESHD when challenged by the COVID-19 MESHD, and special cardiovascular care should be given to these patients.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.